Physician profile
Daniel Neumann
NPI 1609258433
$4,200.86
in general payments reported to CMS, 2019-2025
22 companies · $469 in 2025
The $469 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,955 · 2020: $190 · 2021: $137 · 2022: $413 · 2023: $523 · 2024: $514 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,660.97 | 2019-2023 | Flumist Quadrivalent |
| Tris Pharma INC | $426.91 | 2020-2025 | Dyanavel Xr, Quillivant |
| Supernus Pharmaceuticals, INC. | $362.62 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $263.83 | 2023-2025 | Azstarys |
| Glaxosmithkline, LLC. | $234.28 | 2021-2025 | Bexsero, Pediarix |
| Ironshore Pharmaceuticals INC. | $199.81 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $176.71 | 2019-2023 | Rotateq, Gardasil 9, Vaxelis |
| Pfizer INC. | $161.32 | 2019-2025 | |
| Sanofi Pasteur INC. | $153.39 | 2019-2023 | |
| Cranial Technologies, INC | $130.67 | 2019-2025 | Doc Band |
| Sobi, INC | $115.75 | 2019-2023 | |
| Shire North American Group INC | $66.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.61 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $53.67 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $30.67 | 2025 | Daybue |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $27.16 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $18.43 | 2025 | |
| Seqirus USA INC | $16.04 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.32 | 2023 | |
| Neurelis, INC. | $14.09 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Neumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.